Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneer of advanced haemodialysis solutions, today announces the appointment of Dr Francesco Granata to the Company's Board as an independent Non-Executive Director, with immediate effect.
Dr Francesco Granata has over 35 years of experience in the biopharmaceutical and medical products industries, with strong international commercial expertise. Francesco is currently Chairman of Circassia and also serves on the boards of private companies Italfarmaco SpA, Cell Therapy Ltd and Prismic Pharmaceuticals Inc.
Francesco has previously held senior executive positions at Biogen Idec, including Executive Vice President for global commercial and medical affairs operations, and at Schering-Plough, Group Vice President for Canada and Europe. He has also held roles at Pfizer, as Regional President for Northern Europe and also Middle East and Africa, and as Managing Director at Pharmacia & Upjohn. He started his commercial career in the pharmaceutical industry in R&D, leading the medical division of GlaxoSmithKline in Italy. Francesco practised as a Medical Doctor, specializing in Cardiology, and has a Doctorate of Medicine and Surgery from the University of Pavia, Italy. He was also formerly a member of the Board of the European Federation of Pharmaceutical Industry Associations.
Johan de Ruiter, Chairman of Quanta, commented: "I am very pleased to welcome Francesco to the Quanta Board. His highly relevant experience will be invaluable to the Company as we progress towards commercialisation of our portable, compact haemodialysis system, SC+. To be able to attract such a high quality, senior executive is testament to the enormous potential of our disruptive dialysis technology. I look forward to working with Francesco to bring SC+ to market and to improve the quality of treatment for dialysis patients."
Commenting on his appointment Dr Francesco Granata said: "The technology Quanta is developing for the dialysis market is truly pioneering and I'm looking forward to contributing to the Company's growth as it accelerates the development of SC+. I believe its system has the potential to revolutionise the way haemodialysis patients are currently treated and will bring much needed innovation to an industry where this has been lacking."
SC+ is designed to bring flexibility to dialysis patients and physicians by supporting all treatment regimens, from nurse-assisted care and patient self-care in-centre, to home haemodialysis. SC+ is the only portable, compact haemodialysis system capable of operating at the higher flow rates typically used to treat patients in-centre by traditional machines. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge.
Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company has obtained CE Mark for its flagship product SC+, which is a portable, compact cartridge-based haemodialysis system. SC+ is designed to offer ease-of-use and flexibility whilst facilitating self-care and supporting dialysis patients across the entire continuum of care.
Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008 as a spin out from the FTSE 250 engineering company IMI plc, which remains an investor, with additional funding provided by a group of leading venture capital investors specialised in healthcare: NBGI Ventures, Wellington Partners, Seroba Kernel, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company.
Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.
For more information please visit: http://www.quantafs.com.
About End Stage Renal Disease and Haemodialysis
Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe and End Stage Renal Disease affects millions of patients worldwide. Haemodialysis is a life-saving treatment delivered to an estimated 2 million people globally-with this figure expected to double in the next decade.
At present, haemodialysis is primarily provided by specialist clinics and centres. However this means that the patient is not in control of when they can dialyse. It is clinically proven that more regular dialysis improves outcomes and quality of life for the patient, and a number of studies have shown that 30-40% of patients would be capable of performing self-dialysis.
Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis, but a major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems. SC+ addresses these issues and puts the patient at the centre, allowing them to take greater control of their treatment.
For more information about Quanta, please contact:
John E. Milad,
Chief Executive Officer
E: [email protected]
Consilium Strategic Communications
Amber Fennell / Matthew Neal / Lindsey Neville
E: [email protected]
SOURCE Quanta Fluid Solutions Ltd